皇冠体育app

• Healthcare and life sciences company Ipsen invests 拢22million at its North Wales site

• Ipsen pledges its commitment to Wales post EU Exit

Secretary of State for Wales Alun Cairns will visit North Wales today (17 November 2017) to welcome global healthcare company Ipsen鈥檚 拢22million investment at its Wrexham site.

皇冠体育app announcement cements the organisation鈥檚 commitment to the UK healthcare arena and further underlines Wales鈥� growing reputation as a centre of excellence for life sciences.

Ipsen is the third biggest employer in the area with approximately 400 employees. Today鈥檚 announcement will see its Wrexham footprint expand to increase research and manufacturing capacity with new packing line capability and a new office environment.

Life sciences is one of Wales鈥� fastest growing sectors. It has a turnover of around 拢2 billion and employs around 11,000 people in over 350 companies.

皇冠体育app UK鈥檚 strengths in science, research and innovation are also a major focus of the government鈥檚 industrial strategy.

皇冠体育app Secretary of State will also tour global medical products and technologies company ConvaTec in Deeside.

Welcoming the announcement Secretary of State for Wales Alun Cairns said:

Ipsen is one of North Wales鈥� great success stories. 皇冠体育appir continued expansion is a clear demonstration of the significant contribution life sciences and innovation in these specialist areas make to the region and to the Welsh economy.

皇冠体育app continued growth of Ipsen鈥檚 presence in Wrexham demonstrates its commitment to North Wales and to its skilled workforce. 皇冠体育appse are exciting times for the company and for the sector in Wales as a whole as we look to establish ourselves as a world class hub of excellence in life sciences research and development.

Ipsen sell products in 115 countries worldwide, has operated in Wrexham since 1995, with more than 25 years of experience, manufacturing and development of innovative specialty care products. 皇冠体育app site at Wrexham produces one of Ipsen鈥檚 key strategic products Dysport庐, which is approved in 80 countries and in several therapeutic indications such as cerebral palsy, spasticity and cervical dystonia.

Aidan Murphy, Senior Vice President, Biotech Development and Manufacturing at Ipsne said:

We are delighted by today鈥檚 announcements as we take important strides in the accelerated expansion programme underway at Wrexham which will see production grow significantly to reflect demand and company ambition.

皇冠体育app manufacture of Dysport庐 remains a highly complex process, difficult to replicate and utilises expert and unique technology. We are fortunate to work with a group of highly-skilled individuals across all parts of the organisation at Wrexham and know that this expansion reinforces the site鈥檚 position as a state-of-the-art medicine manufacturing facility located here in the UK.

Ewan McDowall, General Manager Ipsen UK & Ireland, commented on the continued investment in the UK saying,

皇冠体育app UK remains a pioneer of healthcare, life sciences and technology, and Ipsen will continue to invest and support this growth. 皇冠体育app political environment is in a period of uncertainty, however Ipsen is confident that the UK remains an important location for Ipsen across research, development, manufacturing, and of course patients鈥� access to medicines.

We look forward to increasing opportunities to collaborate with experts across each stage of medicine development, manufacturing and distribution 鈥� as patients don鈥檛 have time to wait.

Alun Cairns added:

Ipsen is an important inward investor in Wales. As we prepare to leave the EU, this government is committed through our Industrial Strategy to ensuring the UK remains one of the best places in the world to do business.